In-Depth Study on Hormone Refractory Prostate Cancer - Pipeline Review, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Hormone Refractory Prostate Cancer (Oncology) pipeline landscape.

Prostate cancer no longer responds to hormone therapy and growth of the cancer continues, it is called hormone resistant or hormone refractory prostate cancer. This occurs if cancer cells do not need testosterone for growth. Symptoms include fatigue, blood in the urine, pain in the hips, back (spine), chest (ribs), or other areas from cancer spread to bones, loss of appetite, or weight loss. Predisposing factors include age, smoking and family history. Treatment includes chemotherapy and radiotherapy.

Complete report available @ Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016

Report Highlights

This report provides comprehensive information on the therapeutics under development for Hormone Refractory Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hormone Refractory Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 9, 57, 35, 1, 36 and 2 respectively for Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 2, 7 and 4 molecules, respectively for Hormone Refractory Prostate Cancer.

Hormone Refractory Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hormone Refractory Prostate Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Hormone Refractory Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hormone Refractory Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hormone Refractory Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Hormone Refractory Prostate Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hormone Refractory Prostate Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hormone Refractory Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

AB Science SA AbbVie Inc Adamis Pharmaceuticals Corporation Advaxis, Inc. Aeterna Zentaris Inc. Ambrx, Inc. Amgen Inc. AnGes MG, Inc. Aphios Corporation ARMO Biosciences, Inc. Armour Therapeutics Inc. Arno Therapeutics, Inc. ArQule, Inc. Arrowhead Pharmaceuticals, Inc. Arvinas, Inc. Asana BioSciences, LLC Astellas Pharma Inc. AstraZeneca Plc ATLAB Pharma SAS Bavarian Nordic A/S Bayer AG Bio-Cancer Treatment International Limited Biscayne Pharmaceuticals, Inc. Boehringer Ingelheim GmbH Bristol-Myers Squibb Company CellCentric Ltd Celldex Therapeutics, Inc. Corcept Therapeutics Incorporated Corvus Pharmaceuticals, Inc. Curevac AG CytoVac A/S DexTech Medical AB Eli Lilly and Company Enceladus Pharmaceuticals BV Endo Pharmaceuticals Inc. Endocyte, Inc. Errant Gene Therapeutics, LLC ESSA Pharma Inc F. Hoffmann-La Roche Ltd. Fujifilm Corporation G1 Therapeutics, Inc. Genentech, Inc. Genmab A/S Gilead Sciences, Inc. Glactone Pharma AB GlaxoSmithKline Plc GTx, Inc. Hybrigenics S.A. Immunomedics, Inc. Io Therapeutics, Inc. Ionis Pharmaceuticals, Inc. Jiangsu Hengrui Medicine Co., Ltd. Johnson & Johnson Jyant Technologies, Inc. Kura Oncology, Inc. MedImmune, LLC Mediolanum farmaceutici S.p.A. Medivation, Inc. MEI Pharma, Inc. Merck KGaA Millennium Pharmaceuticals Inc NewLink Genetics Corporation Novartis AG Oncogenex Pharmaceuticals, Inc. Oncolytics Biotech Inc. Ono Pharmaceutical Co., Ltd. Oric Pharmaceuticals Inc Orion Oyj Orphagen Pharmaceuticals, Inc. Pfizer Inc. Progenics Pharmaceuticals, Inc. Selexel Sotio a.s. Supratek Pharma Inc. Taiho Pharmaceutical Co., Ltd. Takeda Pharmaceutical Company Limited Tesaro, Inc. Tiltan Pharma Ltd. Tokai Pharmaceuticals, Inc. TRACON Pharmaceuticals, Inc. UbiVac, LLC Viralytics Ltd. Zenith Capital Corp

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###